Moderna Inc. released details of its plan for analyzing data from its COVID-19 vaccine trial, offering an unusual under-the-hood look at the study of a top vaccine candidate.
In a statement ahead of an investor meeting the company is holding on Thursday, Moderna said the trial has now enrolled 25,296 of an expected 30,000 volunteers, and more than 10,000 have received two doses of the vaccine.
Join BJL status for engagements, births, deals, levayos, events & more: bit.ly/32HUBnJ
Join an official BJL WhatsApp group for breaking news as it happens: bit.ly/34zdGuF
While the broad outlines of major drug trials are available on a U.S. government website, details of how and when data-monitoring boards overseeing the trials plan to analyze data are often kept confidential by pharmaceutical companies.
However, the unprecedented push to get a vaccine to market quickly has increased interest in those details. The analysis of findings and what the rules are for stopping a trial if there are encouraging early signals could determine how quickly a shot receives emergency authorization from U.S. regulators.
Read more at NEWSMAX.